Last reviewed · How we verify
NCT06579378
Feasibility Study of Virtual Sail 3D in Cognitive Functions
NA trial testing VSail 3D in Mild Cognitive Impairment in 40 participants. Currently enrolling.
1 November 2025
Quick facts
| Lead sponsor | University of Cagliari |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 May 2024 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- VSail 3D
- WEB-Health
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Sponsor
University of Cagliari
Who can join
65 and older, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research project will assess the feasibility and preliminary effectiveness of a 6-week intervention to improve cognitive functions using the 3D immersive virtual reality software "CEREBRUM" with virtual sailing scenarios among elderly with mild cognitive impairment. CEREBRUM, developed by PRoMIND in association with IDEGO, is the first European tool for enhancing cognitive functions via 3D immersive virtual reality in psychosocial disabilities. Previous studies have shown its effectiveness in improving cognitive functions and well-being in people with bipolar disorders. The software includes modules for memory, learning, cognitive estimations, attention, working memory, and executive functions. For this study, the software was developed with sailing virtual scenarios to make it more enjoyable and engaging, as well as to train other cognitive functions such as motor skills and language abilities among people with disabilities.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Enhancing Cognitive Functions in Older Adults With Mild Cognitive Impairment via Virtual Sail 3D: Protocol for a Feasibility Randomized Controlled Trial.
Sancassiani F, Perra A, Vacca V, Montisci R, et al · · 2026 · PMID 41538788 · DOI 10.2196/85089
Verify or expand the search:
- PubMed search for NCT06579378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other University of Cagliari trials
Trials by the same sponsor.
- NCT06872151 — Evaluation of the Effectiveness of a Topical Medical Device in Wound Healing and Symptom Relief in the Postoperative Per · Phase 4 · completed
- NCT06523920 — Protecting Autologous Free Flaps From Ischemia/Reperfusion Damage With Cold Storage. · NA · not yet recruiting
- NCT06484205 — Evaluation of the Effectiveness of the World Health Organization QualityRights Training in Italy · NA · recruiting
- NCT06526962 — 5Fr Bipolar Electrode vs. Conical Optical 5Fr Fibers for Dual Wave-length Diode Laser for Hysteroscopic Polypectomy · recruiting
- NCT06270966 — Cognitive Remediation VR Tool for People With MCI: a Feasibility RCT · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06579378 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cagliari
- Last refreshed: 30 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06579378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing